Viral Vector
The use of viral vectors to deliver antigens that elicit targeted robust immune responses has been used for several decades.1 From SV40 to adenoviruses, herpesviruses, vesicular stomatitis, and lentiviruses, numerous vector systems have been explored.2,3
The video below will highlight the modes of action and benefits of some commonly used viral vector, adenoviral vectors:
References
- Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010;8(1):62-73.
- Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A. 1972;69(10):2904-9.
- Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505-18.
- Pinschewer DD. Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly. 2017;147:w14465.
- Lawrence S and Richard S. Vaccines of the future. Underst. Mod. Vaccines Perspect. Vaccinol. 2011; 1(1): 151–99
- Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther. 2014;25(4):301-17.
- Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013;12(4):379-93.
- Rauch S, Jasny E, Schmidt KE, Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018;9:1963.
- Milicic A, Rollier CS, Tang CK, Longley R, Hill AVS, Reyes-Sandoval A. Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. Sci Rep. 2017;7(1):7284.
Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.
LOCs to insert local adverse events reporting procedure.
© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.
NX-GBL-GVX-WCNT-220014 | November 2022